Aquilon Pharma Overview
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Series B
- (Cancelled)
- Investors
-
5
Aquilon Pharma General Information
Description
Operator of a pharmaceutical firm intended to develop drugs for the treatment of pulmonary diseases. The company's firm focuses on the development of drugs for the treatment of respiratory disorders and enhances both the lung deposition and the pharmacology of existing drugs for asthma and chronic obstructive pulmonary disease (COPD), enabling patients to get efficient inhalation drugs for respiratory problems.
Contact Information
Website
www.aquilonpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
- Quai de la Boverie 59
- Walloon Region
- 4020 Liege
- Belgium
+32 04 000 00 00
Aquilon Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | Cancelled | Generating Revenue | ||||
| 3. Early Stage VC | 12-Dec-2018 | 00.00 | 00.000 | Completed | Generating Revenue | |
| 2. Angel (individual) | 26-Oct-2015 | $388K | $388K | 00000 | Completed | Generating Revenue |
| 1. Accelerator/Incubator | 14-Nov-2011 | Completed | Generating Revenue |
Aquilon Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 000 | 00000.00 | 00000.00 | 00 | 00000.00 | 00.000 |
Aquilon Pharma Patents
Aquilon Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4003320-A1 | Golf ball-like microparticles for use in the treatment and prevention of pulmonary diseases | Pending | 10-Sep-2019 | 0000000000 | |
| CA-3150551-A1 | Golf ball-like microparticles for use in the treatment and prevention of pulmonary diseases | Pending | 10-Sep-2019 | 0000000000 | |
| EP-3993810-A1 | Inhalable composition comprising cyclodextrin for use in the treatment of nasal inflammations | Pending | 01-Jul-2019 | A61K31/724 |
Aquilon Pharma Executive Team (10)
Aquilon Pharma Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Didier Cataldo | Aquilon Pharma | Co-Founder, Chairman of Scientific Committee, Administrator & Board Member | 000 0000 |
| Frank Pieters | Aquilon Pharma | Chairman of the Executive Team BD & Strategy and Board Member | 000 0000 |
| Paul Maes | Aquilon Pharma | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
Aquilon Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Aquilon Pharma Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Noshaq | Venture Capital | Minority | 000 0000 | 000000 0 | |
| SambrInvest | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Scale Investment Funds | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Be Angels | Angel Group | Minority | 000 0000 | 000000 0 | |
| WBC Ventures | Accelerator/Incubator | 000 0000 | 000000 0 |